Phd in NETWORK ONCOLOGY AND PRECISION MEDICINE

Research: Integrative Radiogenomic Approach to Predict Chemotherapy Response in Advanced High-Grade Serous Ovarian Cancer

MD – Board-Certified Specialist in Diagnostic Radiology

EDUCATION AND TRAINING
November 2025 – Present PhD Program (41st cycle) in Network Oncology and Precision Medicine Sapienza Università di Roma
November 2021 – October 2025 Residency in Diagnostic Radiology – Final grade: 70/70 with honors Sapienza Università di Roma – Policlinico Umberto I. Specialization Thesis: “Validation of radiomic models in magnetic resonance imaging for the classification and risk stratification of ovarian masses” Supervisor: Prof. Lucia Manganaro
October 2012 – June 2021 MD Degree in Medicine and Surgery – Final grade: 107/110 Sapienza Università di Roma Medical Degree Thesis: “Risk factors for preterm birth: correlations with neonatal outcomes and preventive strategies” Supervisor: Prof. Pasquale Mancino
October 2020: Basic Life Support (BLS) Certification American Heart Association

PROFESSIONAL EXPERIENCE
November 2021 – October 2025: Resident in Diagnostic Radiology Sapienza Università di Roma – Policlinico Umberto I Clinical and research activities with particular focus on: Oncologic CT and MRI imaging Female urogenital imaging Obstetric and fetal imaging Multiparametric MRI (DWI, ADC, IVIM) Radiomics and quantitative imaging analysis Assessment of therapeutic response in gynecologic oncology
September 2021 – October 2021: Vaccination Physician – SARS-CoV-2 National Vaccination Campaign ACEA Pfizer Vaccination Hub, Rome Administration of COVID-19 vaccines, pre-vaccination clinical assessment, informed consent management, and post-vaccination monitoring within the Italian national vaccination program.

SPECIFIC SKILLS
Clinical Radiology Expertise Oncologic CT and MRI Female urogenital imaging (ovarian, endometrial, and cervical malignancies) Obstetric and fetal MRI Multiparametric MRI (DWI, ADC mapping, IVIM) Imaging-based assessment of treatment response in gynecologic oncology Quantitative Imaging and Radiomics Radiomic feature extraction and analysis Use of DeepTrace – Trace4Research platform Tumor segmentation and ROI-based quantitative analysis Integration of imaging data with clinical and molecular datasets Information Systems Advanced use of multiple hospital RIS and PACS systems Clinical-radiological database management for retrospective and prospective studies
Research Skills Design of clinical-radiological studies Critical appraisal of scientific literature Scientific manuscript preparation Research activity in radiomics and radiogenomics

RESEARCH ACTIVITY
PhD Project Title: "Integrative Radiogenomic Approach to Predict Chemotherapy Response in Advanced High-Grade Serous Ovarian Cancer" This PhD project is positioned within the field of precision oncology and aims to develop an integrated radiogenomic model in patients with advanced-stage high-grade serous ovarian cancer (HGSOC). The study is prospective, monocentric, and designed to enroll 60 patients with newly diagnosed, histologically confirmed advanced HGSOC who are not eligible for primary cytoreductive surgery. All patients will undergo baseline CT and multiparametric MRI examinations.
Primary Objectives To investigate associations between CT- and MRI-derived imaging biomarkers and: Histopathological features Serum biomarkers (CA-125, circulating miRNAs) Tumor genomic profiles To assess the prognostic value of radiogenomics in predicting chemotherapy response, measured by the Chemotherapy Response Score (CRS) To identify correlations between radiomic signatures and chemotherapy resistance Methodology Multiparametric MRI (including DWI and quantitative analysis) Texture analysis and radiomic feature extraction Integration of radiological, histopathological, and genomic data Development of predictive algorithms for: Treatment response Disease-Free Survival (DFS) Overall Survival (OS) The ultimate goal is to establish a prognostic radiogenomic signature capable of supporting therapeutic stratification and advancing personalized treatment strategies in advanced ovarian cancer.